Highlights from Apellis Pharmaceuticals' Third Quarter 2025
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) recently reported impressive financial results for the third quarter of 2025. The company generated a total of $459 million in revenue, with $178 million stemming from net product sales in the U.S.
Financial Performance Overview
In the first two months following the launch of EMPAVELI, Apellis received 152 new patient start forms for their treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
During this quarter, U.S. net product revenue for EMPAVELI reached $27 million, which reflected a robust initial launch, bolstered by high levels of patient compliance in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Additionally, the product SYFOVRE, which targets geographic atrophy secondary to age-related macular degeneration, achieved U.S. net product revenue of $151 million, marking a 4% growth in total injection demand compared to the previous quarter.
Strong Financial Position and Future Prospects
As of September 30, 2025, Apellis reported cash and cash equivalents totaling $479 million. This healthy financial state is expected to support the company through to sustainable profitability, underlining a strong balance sheet that places them well heading into future growth phases.
Management Insights
Dr. Cedric Francois, CEO of Apellis, commented on the quarter's performance, stating, "The strong execution and progress we achieved this quarter across our product portfolio are remarkably encouraging. The launch of EMPAVELI has been met with recognition within the nephrology community, validating our efficacy and safety profile. Meanwhile, SYFOVRE maintains its leadership in the geographic atrophy market, bringing in reliable revenue that fuels our long-term ambitions."
Strategic Developments and Upcoming Milestones
Apellis has set ambitious targets for continuing the momentum behind EMPAVELI. In the ongoing fight against rare diseases, they have achieved significant milestones:
- Reported $26.8 million in EMPAVELI U.S. net product revenue during Q3 2025.
- On July 28, 2025, EMPAVELI earned the FDA’s approval as the inaugural treatment for C3G and primary IC-MPGN, marking a tremendous step forward for patients previously lacking therapeutic options.
- Plans to initiate two pivotal studies by year-end 2025 focused on focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF), diseases that currently have no approved therapies.
Market Leadership with SYFOVRE
SYFOVRE is rapidly establishing itself as a frontrunner in its market segment. In Q3 2025, revenue reached $150.9 million, showing an upward trajectory in total injections. Notably, SYFOVRE holds an impressive market share of over 60% in the geographic atrophy market, supported by approximately 101k doses administered to physicians during the quarter.
Collaborative Ventures and Financial Agreements
In a strategic move, Apellis entered into a capped royalty purchase agreement with Sobi, further reinforcing its financial outlook. Under this collaboration, Apellis stands to receive up to $300 million, which includes immediate cash of $275 million in exchange for future ex-U.S. royalties on its product via Sobi.
Looking Ahead
With an unwavering commitment to innovation, Apellis Pharmaceuticals is laying a strong foundation for expansion and growth. The company is poised to maintain its upward trajectory, capitalizing on its innovative product offerings and robust financial position, setting the stage for a promising future in the biopharmaceutical industry.
Frequently Asked Questions
What were Apellis Pharmaceuticals' Q3 2025 revenue figures?
Apellis generated $459 million in total revenue, including $178 million from U.S. net product sales.
What is the significance of EMPAVELI for patients?
EMPAVELI is the first FDA-approved treatment for C3G and primary IC-MPGN, providing options for patients who previously had none.
How did SYFOVRE perform in the latest quarter?
SYFOVRE achieved $151 million in U.S. net product revenue, indicating a 4% increase in total injection demand over the last quarter.
What is the current financial status of Apellis?
As of September 30, 2025, Apellis reported cash and cash equivalents of $479 million, supporting its path toward sustainable profitability.
What strategic collaborations does Apellis have?
Apellis collaborates with Sobi, involving a capped royalty purchase agreement, to enhance its financial and commercial strategy moving forward.
